Global RNAi Technology Market - 2023-2030

Global RNAi Technology Market - 2023-2030

Global RNAi Technology Market reached US$ 1.6 billion in 2022 and is expected to reach US$ 3.6 billion by 2030 growing with a CAGR of 10.3% during the forecast period 2023-2030.

Small nucleic acid fragments are employed in RNA interference (RNAi), a technology, to post-transcriptionally silence genes and treat cancer and other disorders. Through the use of this technology, proteins that lack the enzyme pocket required for binding can be made more target-specific.

By using this method, the target genes may be verified and important illness genes can be functionally evaluated, resulting in the creation of potent medicines. Therapeutics based on RNA interference (RNAi) offer a powerful method for rapidly identifying specific and potent inhibitors of disease targets from all molecular classes.

Furthermore, the increased demand for precise gene silencing across a range of applications, including drug development and agricultural biotechnology, expansion of research in these fields is driving up the RNAi technology market size.

Dynamics

Increasing Applications in Molecular Diagnostics (Cancer)

The rise in genetic and metabolic problems, the rise in molecular diagnostics applications, the prevalence of cancer, and the expansion of research and development for drug discovery are some of the factors driving the worldwide RNAi technology market growth. The benefits of RNAi in cancer therapy include efficient growth control of tumors in advanced stages, low cost, and excellent specificity.

Drug resistance might be decreased by using RNAi to simultaneously block several genes in different pathways. For instance, researchers discovered that by inhibiting SH3GL1 with siRNA, the EGFR/ERK/AP-1 pathway might reduce P-glycoprotein expression and reverse MDR. As more efficient delivery technologies are created, RNAi may also be employed to provide tailored medications as chemotherapy adjuvants for particular patients.

Furthermore, metal oxide nanomaterials such as manganese oxide, iron oxide, silica, and metal organic frameworks are also productively used for gene therapy using siRNA. Despite the siRNA carrier capacity, metal oxide nanomaterials have phototherapy and imaging potential due to their magnetic properties, which enable them to be good bioimaging tools for magnetic resonance imaging and combination therapy for theranostics applications.

Rising Drug Approvals

RNA interference mediated by small interfering RNAs (siRNAs) has been exploited to develop therapeutics. siRNAs can be a powerful therapeutic tool because the working mechanisms of siRNAs are straightforward. siRNAs have the advantages of higher specificity than chemical drugs and a high degree of safety. siRNAs are also suitable in terms of efficiency, and candidate groups of siRNA medicines can be developed quickly and easily

As of December 2022, five siRNA drugs have been approved by the US FDA. Patisiran (Onpattro), Givosiran (Givlaari), Lumasiran (Oxlumo), Inclisiran (Leqvio), and Vutrisiran (Amvutta). All five approved siRNA drugs target mRNAs expressed in the liver. This is unsurprising because siRNAs delivered into an animal rapidly accumulate in the liver, a significant organ for detoxifying exogenous materials. However, siRNA drugs targeting mRNAs expressed in other organs are also under development. Moreover, fifteen siRNA therapeutics have progressed to phase 2 and 3 clinical trials. The potential siRNA drugs in phase 3 include nedosiran (DCR-PHXC), ARO-APOC3, fitusiran (ALN-AT3SC), and revusiran (ALN-TTRSC), which target LDH, APOC3, SERPINC1, and TTR, respectively.

Complications related to RNAi Therapeutics and High Costs

Efficacy, toxicity, especially hepatotoxicity due to preferential accumulation in the liver, specificity/favorable biodistribution, off-target accumulation, long-term safety, immunogenicity – as well as issues related to siRNA molecule and its biological actions (off-target effects, immunogenicity, long-term safety, off-target accumulation/RNA-induced silencing complex saturation). Another major issue may be very high drug costs. The current US price tag of Onpattro is approximately US$450,000 per year, which is explained by high development costs and comparably small patient numbers (∼3000 hATTR patients in the USA)

Segment Analysis

The global RNAi technology market is segmented based on type, application, end-user and region.

The Therapeutics Segment Accounted for Approximately 38.2% of the Market Share

Due to the rise in demand for cancer and liver problems, therapeutics is the most rapidly expanding industry. Further, subsectors of the therapeutics market include cancer, liver diseases, neurological disorders, autoimmune disorders, respiratory disorders, ophthalmic disorders, etc.

Due to the increasing demand for better diagnostic and therapeutic approaches for the rising number of cancer cases, the oncology segment held the greatest market share in the global RNAi technology market. The World Health Organization in 2023, estimates that cancer accounts for 8.8 million deaths annually, making it the second largest cause of death worldwide. Globally, cancer is responsible for around one out of every six fatalities.

Over the following two decades, there will likely be a 70% increase in the number of new cases. This barrier can be removed in the clinical use of RNAi-based treatments for the treatment of cancer thanks to recent developments such as the creation of small interfering RNA (siRNA) resistant to nucleases and the discovery of non-viral vectors, including cationic liposomes and nanoparticles. To give accurate treatment, this technology offers a focused approach to cancer therapy. Additionally, it is predicted that the market will have future growth prospects thanks to the expanding medication pipeline, therapy approvals, and clinical trials.

Geographical Analysis

North America accounted for Approximately 39.3% of the Market Share in 2022

Due to the rising need for RNAi technology for treatment purpose in healthcare, manufacturers in North America have chances of increasing their operations. Increasing application of RNAi Technology in the healthcare industry and rising awareness among people, advancement of technologies for treatment, and increase in biopharmaceutical establishment across the region are also contributing to the growth of the RNAi technology market share of this region.

on April 25, 2023, Ionis Pharmaceuticals, Inc. and its partner Biogen has received U.S. Food and Drug Administration (FDA) approval of QALSODY (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.

With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. It aids in enhancing stability and improving the efficacy of the therapeutics which impacts on the treatment outcome.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global RNAi technology market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting drug development activities worldwide. The COVID-19 pandemic severely disrupted global supply chains, affecting the transportation of raw materials to pharmaceutical manufacturing industries.

Due to an unexpected halt in the research, the gene silencing technology did not move forward in innovations and focused on covid 19 treatment. During the recent pandemic caused by SARS-CoV-2, mRNA-based vaccination strategies have paved the way for a new era of RNA therapeutics. RNA Interference (RNAi) based approach using small interfering RNA may complement the clinical management of COVID-19.

By Type
• Micro RNA
• Small interfering RNA
• Others

By Application
• Drug Discovery and Development
• Therapeutics
Oncology
Liver Disorders
Neurological Disorders
Respiratory Disorders
Autoimmune Disorders
Ocular Disorders
Others
• Others

By End User
• Research and Academic Laboratories
• Diagnostic Laboratories
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On May 18, 2023, pre-clinical data showing that employing INTASYL for silencing CBL-B and TIGIT may be utilized to enhance the anti-tumor response of NK cells, developing a more efficient cell therapy for managing cancer, were released by Phio Pharmaceuticals Corp., a development stage biotechnology business with exclusive INTASYL RNAi platform technology has been developed to enhance the effectiveness of immune cells in killing tumor cells.
• On April 26, 2023, Aln-APP, an investigational RNAi therapy that targets amyloid precursor protein (APP), was developed for the treatment of cerebral amyloid angiopathy (CAA) and Alzheimer's disease, and Regeneron Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. recently announced encouraging preliminary outcomes from the in-progress single ascending dose part of ALN-APP Phase 1 study.
• On January 5, 2023, a master service agreement was signed between Orbit Identification Limited, a pioneer in the identification of therapeutic peptide hits, and SanegeneBio Inc. (Sanegene), a start-up focused on creating new RNAi-based medications. The goal of the partnership is to find effective ways to deliver a variety of RNA therapies to specific tissues in order to effectively knock off disease-causing genes.

Competitive Landscape

The major global players in the RNAi technology market include Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Atalanta Therapeutics, Phio Pharmaceuticals, Benitec Biopharma, Novartis AG, AstraZeneca, Silence Therapeutics, Arbutus Biopharma, and Sylentis S.A. among others.

Why Purchase the Report?
• To visualize the global RNAi technology market segmentation based on type, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of RNAi technology market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global RNAi technology market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies